Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03360890 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
A Phase 2 study of Thyroid Cancer and Salivary Gland Cancer, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT03360890: Active Phase 2 study of Thyroid Cancer and Salivary Gland Cancer, sponsored by University of Chicago.
NCT03360890 is a Phase 2 study of Thyroid Cancer and Salivary Gland Cancer that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 46 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03360890, a Phase 2 study of Thyroid Cancer and Salivary Gland Cancer, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II, 2-cohort, single arm trial treated with the combination of the following two agents: 1. Pembrolizumab (MK3475) 200mg, every three weeks, iv 2. Docetaxel 75mg/m2, every three weeks, iv
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
Study Locations (1)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2032-09 |
| Phase | Phase 2 |
What the registry record for NCT03360890 still lists
NCT03360890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03360890 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03360890 about?
NCT03360890 is a clinical study titled "Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors". Phase II, 2-cohort, single arm trial treated with the combination of the following two agents: 1. Pembrolizumab (MK3475) 200mg, every three weeks, iv 2. Docetaxel 75mg/m2, every three weeks, iv
What is the current status of trial NCT03360890?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2018-03-26. Estimated completion is 2032-09.
What conditions does trial NCT03360890 study?
This clinical trial studies the following conditions: Thyroid Cancer, Salivary Gland Cancer.
What interventions are being tested in trial NCT03360890?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG).
Who is sponsoring clinical trial NCT03360890?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03360890 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03360890's enrollment target sits among peer trials
46 26th of 46 higher than 21 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI